Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy

BACKGROUND: Livedoid vasculopathy is a rare, chronic, and recurrent disease with limited effective treatments. Its etiopathogenesis remains incompletely understood. Baricitinib, a selective Janus kinase 1 and 2 inhibitor, has been used to treat rheumatoid arthritis and could reduce the disease sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yuyang, Tu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646531/
https://www.ncbi.nlm.nih.gov/pubmed/36389811
http://dx.doi.org/10.3389/fimmu.2022.1008392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646531/
https://www.ncbi.nlm.nih.gov/pubmed/36389811
http://dx.doi.org/10.3389/fimmu.2022.1008392

Ejemplares similares